Equities

Scancell Holdings PLC

SCLP:LSE

Scancell Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)13.00
  • Today's Change0.00 / 0.00%
  • Shares traded505.59k
  • 1 Year change44.44%
  • Beta1.2675
Data delayed at least 20 minutes, as of Feb 06 2026 16:13 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.

  • Revenue in GBP (TTM)4.71m
  • Net income in GBP-5.51m
  • Incorporated2008
  • Employees60.00
  • Location
    Scancell Holdings PLCUnit 202 Bellhouse BuildingSanders Road, Oxford Science ParkOXFORD OX4 4GDUnited KingdomGBR
  • Phone+44 18 6558 2066Fax+44 11 5823 1863
  • Websitehttps://www.scancell.co.uk/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m30.68m10.0030.68m10.00
ImmuPharma PLC0.00-3.93m32.73m6.0032.73m6.00
hVIVO PLC51.28m5.28m41.91m301.0041.91m301.00
Skinbiotherapeutics PLC4.64m-696.25k54.37m41.0054.37m41.00
Hemogenyx Pharmaceuticals PLC0.00-7.81m59.93m16.0059.93m16.00
4Basebio PLC1.78m-14.41m87.02m--87.02m--
Bioventix PLC13.12m7.58m90.91m16.0090.91m16.00
Scancell Holdings Plc4.71m-5.51m134.91m60.00134.91m60.00
Faron Pharmaceuticals Oy0.00-26.94m188.15m25.00188.15m25.00
Avacta Group Plc-11.09m-33.09m264.25m151.00264.25m151.00
Puretech Health PLC4.73m37.47m309.84m56.00309.84m56.00
Data as of Feb 06 2026. Currency figures normalised to Scancell Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

43.70%Per cent of shares held by top holders
HolderShares% Held
Redmile Group LLCas of 08 Sep 2025297.19m28.64%
Vulpes Investment Management Pte Ltd.as of 12 Sep 2025143.54m13.83%
AXA Investment Managers UK Ltd.as of 31 Dec 202512.77m1.23%
Data from 30 Sep 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.